A- A A+

Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.

Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM.

JAMA Netw Open. 2020 Feb 5;3(2):e1920622. doi: 10.1001/jamanetworkopen.2019.20622.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2760032

Naltrexone use in pregnancy: a time for change.

Caritis SN, Venkataramanan R.

Am J Obstet Gynecol. 2020 Jan;222(1):1-2. doi: 10.1016/j.ajog.2019.08.041. 

https://doi.org/10.1016/j.ajog.2019.08.041

A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.

Sullivan MA, Bisaga A, Pavlicova M, Carpenter KM, Choi CJ, Mishlen K, Levin FR, Mariani JJ, Nunes EV.

Am J Psychiatry. 2019 Feb 1;176(2):129-137. doi: 10.1176/appi.ajp.2018.17070732. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358483/

Acceptability and efficacy of naltrexone for criminal justice‐involved individuals with opioid use disorder: a systematic review and meta‐analysis.

Bahji, A., Carlone, D., and Altomare, J. ( 2019) 

Addiction, doi.org/10.1111/add.14946.

Abstract

https://onlinelibrary.wiley.com/doi/abs/10.1111/add.14946?campaign=wolacceptedarticle

Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.

Friedmann PD, Wilson D, Hoskinson R Jr, Poshkus M, Clarke JG.

J Subst Abuse Treat. 2018 Feb;85:45-48. doi: 10.1016/j.jsat.2017.04.010. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648627/

Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.

Velasquez M, Flannery M, Badolato R, Vittitow A, McDonald RD, Tofighi B, Garment AR, Giftos J, Lee JD.

Addict Sci Clin Pract. 2019 Oct 1;14(1):37. doi: 10.1186/s13722-019-0166

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771097/

Rizmoic / Nalmedine 200 Mikrogramm Filmtabletten - ZUSAMMENFASSUNG DER MERKMALE DES ARZNEIMITTELS

Rizmoic wird angewendet zur Behandlung von Opioid-induzierter Obstipation (OIC, opioid-induced constipation) bei Erwachsenen, die früher bereits mit einem Abführmittel behandelt wurden. (Europäische Arzneimittel-Agentur, 2019)

https://www.ema.europa.eu/en/documents/product-information/rizmoic-epar-product-information_de.pdf

A Review of Samidorphan: A Novel Opioid Antagonist.

Chaudhary AMD, Khan MF, Dhillon SS, Naveed S.

Cureus. 2019 Jul 15;11(7):e5139. doi: 10.7759/cureus.5139. Review.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6741386/

Letter to the Editor: Response to Darke S, et al. Circumstances of death of opioid users being treated with naltrexone. 

Streel, E., and Brewer, C. ( 2019)

Addiction, First published: 16 September 2019, doi.org/10.1111/add.14826

https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.14826

Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.

Nunes EV, Bisaga A, Krupitsky E, Nangia N, Silverman BL, Akerman SC, Sullivan MA.

Addiction. 2019 Jul 17. doi: 10.1111/add.14735.

Abstract 

https://www.ncbi.nlm.nih.gov/pubmed/31313402

Circumstances of death of opioid users being treated with naltrexone.

Darke S, Farrell M, Duflou J, Larance B, Lappin J.

Addiction. 2019 Jul 6. doi: 10.1111/add.14729. 

Abstract

https://onlinelibrary.wiley.com/doi/abs/10.1111/add.14729

Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.

Wachman EM, Saia K, Miller M, Valle E, Shrestha H, Carter G, Werler M, Jones H.

Clin Ther. 2019 Jul 27. pii: S0149-2918(19)30346-7. doi: 10.1016/j.clinthera.2019.07.003.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31358302

Opiate Antagonists Do Not Interfere With the Clinical Benefits of Stimulants in ADHD: A Double-Blind, Placebo-Controlled Trial of the Mixed Opioid Receptor Antagonist Naltrexone.

Spencer TJ, Bhide P, Zhu J, Faraone SV, Fitzgerald M, Yule AM, Uchida M, Spencer AE, Hall AM, Koster AJ, Biederman J.

J Clin Psychiatry. 2018 Jan/Feb;79(1). pii: 16m11012. doi: 10.4088/JCP.16m11012.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438372/

Implementing an Opioid Risk Reduction Program in the Acute Comprehensive Inpatient Rehabilitation Setting.

Van SP, Yao AL, Tang T, Kott M, Noles A, Dabai N, Coslick A, Rojhani S, Sprankle LA, Hoyer EH.

Arch Phys Med Rehabil. 2019 May 20. pii: S0003-9993(19)30307-7. doi: 10.1016/j.apmr.2019.04.011.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/31121153

Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.

Springer SA, Di Paola A, Azar MM, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL.

J Acquir Immune Defic Syndr. 2018 May 1;78(1):43-53. doi: 10.1097/QAI.0000000000001634.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889326/

Naltrexone-associated Visual Hallucinations: A Case Report.

Lee DB, Woo YS, Bahk WM.

Clin Psychopharmacol Neurosci. 2019 May 31;17(2):329-331. doi: 10.9758/cpn.2019.17.2.329.

http://www.cpn.or.kr/journal/view.html?volume=17&number=2&spage=329

Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose.

Krieter P, Gyaw S, Crystal R, Skolnick P.

J Pharmacol Exp Ther. 2019 Apr 2. pii: jpet.118.256115. doi: 10.1124/jpet.118.256115.

http://jpet.aspetjournals.org/content/early/2019/04/02/jpet.118.256115.long

Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report.

Ward HB, Barnett BS, Suzuki J.

Subst Abus. 2019 Mar 19:1-6. doi: 10.1080/08897077.2019.1573776.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30888254

Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial.

Krupitsky E, Blokhina E, Zvartau E, Verbitskaya E, Lioznov D, Yaroslavtseva T, Palatkin V, Vetrova M, Bushara N, Burakov A, Masalov D, Mamontova O, Langleben D, Poole S, Gross R, Woody G.

Lancet HIV. 2019 Mar 14. pii: S2352-3018(18)30362-X. doi: 10.1016/S2352-3018(18)30362-X. 

(Registrierung erforderlich)

https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(18)30362-X/fulltext

Naltrexone: A History and Future Directions.

Srivastava B, Gold MS.

Cerebrum. 2018 Sep 1;2018. pii: cer-13-18.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353110/

No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study.

Latif ZE, Solli KK, Opheim A, Kunoe N, Benth JŠ, Krajci P, Sharma-Haase K, Tanum L.

Am J Addict. 2019 Jan 31. doi: 10.1111/ajad.12859. 

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/30701613

Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis

Monica Bolton, Alex Hodkinson, Shivani Boda, Alan Mould, Maria Panagioti, Sarah Rhodes, Lisa Riste and Harm van Marwijk

BMC Medicine2019, 17:10, doi.org/10.1186/s12916-018-1242-0

https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1242-0

Drug combo shows promise in treatment of depression and addiction

The combination of naltrexone and ketamine can help treat both symptoms of addiction and depression, a preliminary study by Yale University researchers suggests. (Yale News, USA, 09.01.2019)

https://news.yale.edu/2019/01/09/drug-combo-shows-promise-treatment-depression-and-addiction

Naltrexone.

Singh D, Saadabadi A.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.2018 Nov 27., PMID: 30521232

https://www.ncbi.nlm.nih.gov/books/NBK534811/

Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study. 

Latif Z, Šaltytė Benth J, Solli KK, et al. 

JAMA Psychiatry.Published online December 19, 2018. doi:10.1001/jamapsychiatry.2018.3537

Abstract

https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2718627

Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

Blum K, Modestino EJ, Badgaiyan RD, Baron D, Thanos PK, Elman I, Siwicki D, Febo M, Gold MS.

EC Psychol Psychiatr. 2018 Aug;7(8):564-579. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226033/

Blocking drug activation as a therapeutic strategy to attenuate acute toxicity and physiological effects of heroin.

Zhang T, Zheng X, Kim K, Zheng F, Zhan CG.

Sci Rep. 2018 Nov 13;8(1):16762. doi: 10.1038/s41598-018-35196-8.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233155/

Long-acting naltrexone has long-acting benefits and 100% induction rates are not difficult to achieve.

Brewer, C., and Streel, E. (2018) 

Addiction, doi.org/10.1111/add.14448.

https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.14448

Extended-release injectable naltrexone (XR-NTX): A response to clinical issues raised by Brewer and Streel.

Jarvis, B. P., Holtyn, A. F., Subramaniam, S., Tompkins, A. D., Oga, E. A., Bigelow, G., and Silverman, K. (2018) 

Addiction, https://doi.org/10.1111/add.14462.

https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.14462

Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.

Toljan K, Vrooman B.

Med Sci (Basel). 2018 Sep 21;6(4). pii: E82. doi: 10.3390/medsci6040082.

https://www.mdpi.com/2076-3271/6/4/82